• The Chinese cancer intervention market reached nearly $41.1 billion in 2016. This market should reach $46.7 billion in 2017 and $89.3 billion by 2022, at a compound annual growth rate (CAGR) of 13.8% through 2022. • Cancer treatment services as a segment should reach nearly $43.9 billion in 2017 and $83.6 billion by 2022, at a CAGR of 13.8% through 2022. • Diagnosis and detection services as a segment should reach nearly $2.9 billion in 2017 and $5.8 billion by 2022, at a CAGR of 15.0% through 2022.
Chapter 1: Introduction
Study Goals and Objectives The Chinese cancer intervention market is big, fast-growing, and dominated by drug and equipment suppliers from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions and which are looking for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehensive understanding of the recent advances and trends in the cancer intervention industry and market in China. Toward this end, this report will cover the market for products for different types of cancer to 2022. The report provides a comprehensive discussion of cancer intervention applications, industry structure, marketing and distribution, partnerships, and companies. The report is designed to aid companies in their strategic planning efforts for accessing cancer intervention industry opportunities in the Chinese market.
Reasons for Doing This Study This study will help pharmaceutical companies, medical equipment suppliers, medical institutions, and drug wholesalers and distributors gain an in-depth understanding on the Chinese cancer intervention market.
Scope of Report The scope of the report includes cancer intervention applications, industries, markets, and companies in China. The markets for cancer intervention are given for the years 2016, 2017 and 2022. The Chinese cancer intervention market includes two major segments: cancer treatment and cancer diagnosis and detection. Each major segment will be further divided and discussed by technology, drug type, end user, etc. In this report, China is referred to as Mainland China. It does not include Hong Kong, Macao and Taiwan. Mainland China has a total of 31 province-level regions, including 22 provinces, four province-level municipalities (cities), and five province-level autonomous regions. Important geographic markets will be discussed, including Beijing, Shanghai and others.
Information Sources Information sources for this report include experts, executives, professors, and officials in the Chinese cancer intervention industry. They are from pharmaceutical companies, associations and governmental departments. Information sources for the study also include online research, patent literature, technical journals, trade magazines, governmental data, public speeches, and conference papers.
Methodology Both primary and secondary research methodologies were used in preparing this study. Estimates of current market demand are made for 2016 and are projected for the next five years from 2017 through 2022. Projections are made in terms of constant U.S. dollars (2016), unadjusted for inflation. Growth is presented in terms of a compound average annual growth rate (CAGR). Sales values are measured at end consumer level; reasons are discussed in the report.
Geographic Breakdown In this report, the geographic regions considered for market analysis include, and only include: North China • Beijing • Hebei • Shanxi • Tianjin • Inner Mongolia East China • Shanghai • Shandong • Zhejiang • Jiangsu • Fujian • Anhui South China • Guangdong • Guangxi • Hainan Middle China • Hubei • Henan • Hunan • Jiangxi Northwest China • Shaanxi • Xinjiang • Gansu • Qinghai • Ningxia
Southwest China • Sichuan • Chongqing • Yunnan • Guizhou • Tibet Northeast China • Liaoning • Heilongjiang • Jilin
Our reports have been used by over 10K customers, including:
Catenin Beta 1 - Pipeline Review, H2 2020
Summary
Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 - Pipeline...
396 pages •
By Global Industry Analysts
• Mar 2021
Project Details:
- StrategyR - A Trademark of Global Industry Analysts, Inc.
- Project Edition: 7
- Influencer Pool: 839
- MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies....
The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 report. The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option...
Active Pharmaceutical Ingredients (API) Market Report Overview Active Pharmaceutical Ingredients (API) market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Active Pharmaceutical Ingredients (API) market types and applications. It is a focused...
372 pages •
By Global Industry Analysts
• Mar 2021
Project Details:
- StrategyR - A Trademark of Global Industry Analysts, Inc.
- Project Edition: 8
- Influencer Pool: 878
- MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies....
120 pages •
By Infiniti Research Limited
• Jan 2021
Global VOC gas monitor market 2021-2025
The analyst has been monitoring the VOC gas monitor market and it is poised to grow by $ 50.05 mn during 2021-2025, progressing at a CAGR of 5% during the forecast period. Our report on VOC gas monitor market provides a holistic analysis, market size and forecast, trends, growth...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences and Roche Holdings AG. The global enzymes market is expected to decline from $7.98 billion in 2019 to $7.81 billion in 2020 at a compound annual growth rate...
Track and Trace Solutions Market by Product Type (Hardware Systems and Software Solutions), Technology (Barcode and RFID), Application (Serialization Solutions and Aggregation Solutions), and End User (Pharmaceutical & Biotechnology Companies, Medical Device Companies, and Others): Global Opportunity Analysis and Industry Forecast,...
Gliosarcoma - Pipeline Review, H2 2020
Summary
latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Pipeline Review, H2 2020, provides an overview of the Gliosarcoma (Oncology) pipeline landscape.
Gliosarcoma is a type of brain tumor that originates from glial cells....
Therapy
Pharmaceutical
Oncology
World
Belgium
Pharmaceutical Registrations
Drug Approval
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.